



PALLA PHARMA

## ASX ANNOUNCEMENT

Wednesday 26 August 2020

### Half Year Results Presentation and Investor Conference Call

Palla Pharma Limited (ASX:PAL) advises that Chief Executive Officer Jarrod Ritchie and Chief Financial Officer Brendan Middleton will host an analyst and investor conference call on Monday, 31 August 2020 at 09.30am AEST to present the Company's results for the half year ended 30 June 2020.

An accompanying presentation will be made available via the ASX announcement platform prior to the call.

### Conference call details

To pre-register for this conference and avoid a queue when calling, please use the following link below:

<https://s1.c-conf.com/diamondpass/10009518-invite.html>

You will be given a unique pin number to enter when you call which will bypass the operator and give you immediate access to the event.

If you are unable to register, then at the time of the conference you can call one of the numbers below and provide the conference ID 10009518 to an operator:

- Attendee Dial-in (Australia Toll Free): 1800 455 963
- Alternate Australia Toll Free: 1800 908 299

This announcement has been authorised for release by the Chairman.

---

### For more information please contact:

Jarrod Ritchie  
Chief Executive Officer  
Palla Pharma Limited  
+61 3 9301 0800

Adrian Mulcahy  
Investor Relations  
Market Eye  
+61 438 630 422 or [ir@pallapharma.com](mailto:ir@pallapharma.com)

Brendan Middleton  
Chief Financial Officer  
Palla Pharma Limited  
+61 3 9301 0800

Tristan Everett  
Media Enquiries  
Market Eye  
+61 403 789 096 or [media@pallapharma.com](mailto:media@pallapharma.com)

---

### About Palla Pharma Limited:

Palla Pharma Limited (ASX:PAL) is a vertically integrated opiate manufacturer from poppy straw growing through to tableting production. Palla Pharma has developed an innovative, efficient and environmentally sustainable opiate manufacturing process based on a unique water-based extraction technology. The company is one of six licensed opiate producers globally, and one of three fully integrated suppliers from opiate extraction through to tableting production delivering on its strategy to secure access to regulated downstream narcotics markets by leveraging its production cost advantage.